DrugPatentWatch Database Preview
Teva Pharm Company Profile
» See Plans and Pricing
What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?
TEVA PHARM has two hundred and eighty-one approved drugs.
There are thirty-three US patents protecting TEVA PHARM drugs. There are thirty-six tentative approvals on TEVA PHARM drugs.
There are four hundred and nine patent family members on TEVA PHARM drugs in thirty-six countries and six hundred and twenty-six supplementary protection certificates in seventeen countries.
Summary for Teva Pharm
| International Patents: | 409 |
| US Patents: | 33 |
| Tradenames: | 237 |
| Ingredients: | 230 |
| NDAs: | 281 |
| Patent Litigation for Teva Pharm: | See patent lawsuits for Teva Pharm |
| PTAB Cases with Teva Pharm as petitioner: | See PTAB cases with Teva Pharm as petitioner |
Drugs and US Patents for Teva Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 202491-004 | Nov 3, 2016 | DISCN | No | No | Start Trial | Start Trial | |||||
| Teva Pharms | TRETINOIN | tretinoin | SOLUTION;TOPICAL | 074873-001 | Jun 19, 1998 | DISCN | No | No | Start Trial | Start Trial | |||||
| Teva Pharms Usa | IFOSFAMIDE/MESNA KIT | ifosfamide; mesna | INJECTABLE;INTRAVENOUS | 075874-001 | Feb 26, 2002 | DISCN | No | No | Start Trial | Start Trial | |||||
| Teva Pharms Usa | SILDENAFIL CITRATE | sildenafil citrate | FOR SUSPENSION;ORAL | 211534-001 | May 29, 2020 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Teva Pharms | PREGABALIN | pregabalin | CAPSULE;ORAL | 091224-004 | Jul 19, 2019 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-006 | Feb 20, 2020 | RX | Yes | Yes | 6,871,646 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | COPAXONE | glatiramer acetate | FOR SOLUTION;SUBCUTANEOUS | 020622-001 | Dec 20, 1996 | 6,054,430 | Start Trial |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | FOR SOLUTION;SUBCUTANEOUS | 020622-001 | Dec 20, 1996 | 6,939,539 | Start Trial |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 6,939,539 | Start Trial |
| Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-002 | Jan 27, 2017 | 6,446,627 | Start Trial |
| Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-001 | Jan 27, 2017 | 6,446,627 | Start Trial |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 6,620,847 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
| ➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
Premature patent expirations for TEVA PHARM
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| Start Trial | Start Trial |
International Patents for Teva Pharm Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101618933 | Start Trial |
| China | 105597204 | Start Trial |
| Germany | 60107107 | Start Trial |
| Canada | 2926432 | Start Trial |
| Eurasian Patent Organization | 035329 | Start Trial |
| European Patent Office | 3057637 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharm Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0526171 | 31/2001 | Austria | Start Trial | PRODUCT NAME: NATEGLINIDE; NAT. REGISTRATION NO/DATE: EU/1/01/174/001 - EU/1/01/174/021 20010403; FIRST REGISTRATION: LI 55401.01 - 02 20000928 |
| 1412357 | C 2008 016 | Romania | Start Trial | PRODUCT NAME: SITAGLIPTIN OPTIONAL SUB FORMA DE SARE ACCEPTABILAFARMACEUTIC IN SPECIAL MONOFOSFAT + METFORMIN OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC IN SPECIALCLORHIDRAT; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/455/001 - RO EU/1/08/455/014; DATE OF NATIONAL AUTHORISATION: 20080716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): CH 58450 01, CH 58450 02, CH 58450 03; DATE OF FIRST AUTHORISATION IN EEA: 20080408 |
| 0387077 | SPC/GB04/003 | United Kingdom | Start Trial | PRODUCT NAME: PARICALCITOL; REGISTERED: ES SPAIN 64.974 20020809; UK PL 00037/0403 20030721 |
| 0617614 | SPC/GB01/014 | United Kingdom | Start Trial | PRODUCT NAME: ALITRETINOIN; REGISTERED: UK EU/1/00/149/001 20001018 |
| 0961612 | 09C0050 | France | Start Trial | PRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE: EU/1/07/428/001 20080111 |
| 1301519 | 122016000024 | Germany | Start Trial | PRODUCT NAME: TENOFOVIRALAFENAMID ODER EIN SALZ ODER SOLVAT DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 20151119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
